Novo Nordisk, Hims & Hers announce obesity care collaboration

Novo Nordisk (NVO) and Hims & Hers (HIMS) announced a long-term collaboration designed to make proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. As a first step, Americans can now access NovoCare Pharmacy directly through the Hims & Hers platform, with a bundled offering of all dose strengths of Wegovy and a Hims & Hers membership, which includes access to 24/7 care, ongoing clinical support, and nutrition guidance, all in one place. At a single, unified price starting at $599 per month, individuals may be prescribed Wegovy, alongside Hims & Hers’ approach to care, powered by technology. The offering is available this week on the Hims & Hers platform. The companies are also developing a roadmap that combines Novo Nordisk’s treatments with Hims & Hers’ ability to scale access to care, aiming to improve long-term outcomes for more people, more affordably.